Full Press Release Details
Rhythm Pharmaceuticals Presents Data from Phase 2 and Long term Extension Trials Evaluating Setmelanotide for the Treatment of Hypothalamic Obesity at ObesityWeek and Plans to Init.
RYTM
Rhythm Pharmaceuticals Presents Data from Phase 2 and Long term Extension Trials Evaluating Setmelanotide for the Treatment of Hypothalamic Obesity at ObesityWeek and Plans to Init
Key Takeaway: Rhythm Pharmaceuticals Presents Data from Phase 2 and Long term Extension Trials Evaluating Setmelanotide for the Treatment of Hypothalamic Obesity at ObesityWeek and Plans to Init